The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:1504 November 30, 1995 Number 22
NextNext

Optimal Oral Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation and Recent Cerebral Ischemia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: The European Atrial Fibrillation Trial demonstrated the efficacy of anticoagulant therapy in preventing stroke in high-risk patients with atrial fibrillation.1 The results were convincing because the number of events among untreated patients was large and the number of events among those treated with anticoagulants was small. Further analysis of the small group of events occurring among patients in the trial who were treated with anticoagulants can provide only a preliminary step toward the critical goal of specifying precisely the optimal range of anticoagulation for atrial fibrillation.

Strong evidence that low intensities of anticoagulation are effective has facilitated . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.